SIGi001-A-9 Dox inducible NGN2
SIGi001-A-17
General
iPSC Line |
|
| hPSCreg name | SIGi001-A-17 |
| Cite as: | SIGi001-A-17 |
| Alternative name(s) |
SIGi001-A-9 Dox inducible NGN2
|
| iPSC line type | Human induced pluripotent stem cell (hiPSC) |
| Similar iPSC lines |
SIGi001-A (IPSC0028 parental, SAMEA4447455) SIGi001-A-1 (iPSC0028 SLC17A7/GFP E3) SIGi001-A-2 (iPSC0028 SLC17A7/GFP C3) SIGi001-A-3 (iPSC0028 MAPT P301L C4) SIGi001-A-4 (iPSC0028 MAPT P301L D4) SIGi001-A-5 (iPSC0028 MAPT P301S 1C9C4) SIGi001-A-6 (iPSC0028 MAPT P301S 1B9C9) SIGi001-A-7 (iPSC0028 MAPT P301S 2G2B7) SIGi001-A-8 (iPSC0028 MAPT P301S+Ex10+16/Clone 7D11A7) SIGi001-A-9 (iPSC0028 MAPT P301S+Ex10+16/Clone 7H6A1) SIGi001-A-10 (iPSC0028 MAPT P301S+Ex10+16/Clone 7G4A8) SIGi001-A-11 (iPSC0028 MAPT P301S+Ex10+16/Clone 7C6A4, SAMEA4451118) SIGi001-A-21 (SIGi001-AAVS1-FRT) SIGi001-A-22 (SIGi001-ICAM1-GFP) SIGi001-A-23 (SIGi001-HC3x) SIGi001-A-24 (SIGi001-HC3x-ICAM1-GFP) SIGi001-A-12 (iPSC0028 - BiAllelic MAPT_Ex10+16T/Clone 1F5-D12, SAMEA104237570) SIGi001-A-13 (iPSC0028 – MonoAllelic MAPT_Ex10+16T/Clone 1D01-11) SIGi001-A-14 (SIGi001-A Bi-Allelic MAPT HA-tag) SIGi001-A-15 (SIGi001-A Dox inducible NGN2) SIGi001-A-16 (SIGi001-A-9 Bi-Allelic MAPT HA-tag) SIGi001-A-18 (SIGi001-A-12 Bi-Allelic MAPT HA-tag #U28-12-P29-5) SIGi001-A-19 (SIGi001-A-12 Dox inducible NGN2) |
| Last update | 4th June 2026 |
| User feedback | |
Provider |
|
| Generator | Bioneer (BION) |
| Owner | Bioneer (BION) |
| Distributors | |
External iPSC Databases |
|
| BioSamples | SAMEA6080816 |
General iPSC Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
iPSC Genetic Modification
| Disease/phenotype related modifications |
|
| Genetic modifications not related to a disease |
|
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Family history | no |
| Is the medical history available upon request? | no |
| Is clinical information available? | no |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA4447434 |
Ethics
Also have a look at the ethics information for the parental line
SIGi001-A
.
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
iPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
SIGi001-A.
|
|
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Virus (Retrovirus) |
| Is the used vector excisable? |
No |
| Absence of reprogramming vector(s)? |
No |
| Reprogramming vectors silenced? |
Unknown |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
iPSC Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzymatically
Accutase
|
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
| Has Rock inhibitor (Y27632) been used at passage previously with this iPSC line? | Yes |
iPSC Characterisation
Analysis of undifferentiated iPSCs
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| SSEA-1 |
No |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
||||
| SSEA-4 |
Yes |
|
Differentiation Potency
In vitro directed differentiation
Protocol or reference
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
Genotyping
Karyotyping (iPSC Line) |
|
Other Genotyping (iPSC Line) |
Login to share your feedback, experiences or results with the research community.